URAC Opioid Stewardship Designation Consulting — Integral Healthcare Solutions

Last updated: April 2026

IHS guides pharmacies, pharmacy benefit managers, health plans, and patient care management organizations through URAC's Opioid Stewardship Designation — a 4-standard add-on credential that demonstrates your organization's commitment to responsible opioid management, patient safety, and reducing substance use disorder risk. Our principal, Thomas G. Goddard, JD, PhD, served as the former Chief Operating Officer and General Counsel of URAC, giving IHS an authoritative and precise understanding of how URAC builds, interprets, and applies its standards.

What Is the URAC Opioid Stewardship Designation?

The URAC Opioid Stewardship Designation is an optional add-on designation developed by URAC to promote patient safety and the appropriate use of opioid medications, encourage innovation in opioid management, and decrease the risk of substance use disorder. It is not a standalone accreditation — it supplements an existing URAC accreditation or certification (URAC).

The designation comprises four standards. That focused scope makes it one of the more streamlined URAC credentials to pursue — but each standard requires operational evidence, URAC-aligned policies, and documented staff training. The standards address: opioid prescribing appropriateness and oversight, patient safety protocols, innovation in opioid management and monitoring, and substance use disorder risk reduction.

Definition: What Is Opioid Stewardship?

Opioid stewardship refers to coordinated, systematic efforts to promote safe and appropriate opioid prescribing, dispensing, and monitoring — while minimizing harms including addiction, overdose, and diversion. In a healthcare organization context, it encompasses clinical protocols, patient education, data monitoring, prescriber oversight, and escalation pathways. URAC's designation operationalizes these principles into auditable organizational standards.

The Opioid Context

Despite meaningful progress — overdose deaths fell an estimated 26.9% from 2023 to 2024 (CDC), with fentanyl-related deaths declining sharply — the opioid crisis remains a defining public health challenge. From 1999 through 2023, approximately 806,000 people died from an opioid overdose (Drug Abuse Statistics). At least 40 states reported increases in opioid fatalities during the COVID-19 pandemic. Pharmacists and pharmacy organizations are among the most accessible frontline actors in opioid stewardship — and payers, regulators, and health systems are increasingly expecting formal documentation of stewardship commitments.

Who Needs the URAC Opioid Stewardship Designation?

Any organization that holds or is actively pursuing a qualifying URAC program and that touches patient access to or use of opioid medications should evaluate this designation. That includes:

  • Specialty pharmacies — particularly those dispensing controlled substances for chronic pain, oncology, or post-surgical patients
  • Mail service pharmacies — managing high-volume opioid prescription fulfillment with limited patient face time
  • Pharmacy benefit managers (PBMs) — overseeing opioid utilization management across large member populations
  • Health plans and managed care organizations — with formulary authority and clinical programs affecting opioid access
  • Patient care management and case management organizations — coordinating care for members with opioid use disorder or chronic pain
  • Digital health and telehealth organizations — whose platforms influence opioid prescribing or patient education
  • Workers' compensation and property and casualty pharmacy benefit managers — managing opioid utilization in injury-related populations

Organizations pursuing Specialty Pharmacy Accreditation, PBM Accreditation, or Health Plan Accreditation from URAC are the most natural candidates. The designation can be pursued concurrently with the primary accreditation or added after.

The URAC Opioid Stewardship Designation Process

The Opioid Stewardship Designation follows URAC's standard accreditation review process, applied to the four-standard designation set. Because it is an add-on credential, the timeline aligns with or follows the primary accreditation engagement. Here is how IHS structures the work.

Phase 1: Eligibility Confirmation and Gap Assessment

IHS confirms your organization's eligibility — verifying that your primary URAC program qualifies as an associated program for the Opioid Stewardship Designation and that your operations touch opioid patient access or use. We then conduct a gap assessment across all four designation standards, identifying policy gaps, operational deficiencies, and documentation requirements. Many organizations pursuing specialty pharmacy or PBM accreditation have partial opioid stewardship documentation in place — the gap assessment identifies what is missing versus what needs to be formalized.

Phase 2: Policy and Documentation Development

IHS provides policy templates, protocol frameworks, and documentation structures aligned with URAC's Opioid Stewardship Designation standards and interpretive information. This includes opioid prescribing appropriateness protocols, patient safety monitoring procedures, substance use disorder risk screening documentation, staff training records, and escalation pathway documentation. Your team adapts templates to your organization's specific patient population, formulary, and clinical workflows.

Phase 3: Operational Implementation and Evidence Generation

Policies must be operationally live — generating audit-ready evidence — before the URAC review date. IHS monitors implementation, conducts internal mock reviews against URAC's four standards, and identifies documentation gaps before the formal submission. The mock review process catches the predictable deficiency categories before URAC reviewers do.

Phase 4: Application and Review Support

IHS supports the formal URAC application process, coordinates documentation submission, and provides direct support if URAC issues Requests for Information (RFIs) during the review. Given the four-standard scope, well-prepared organizations typically move through the review process efficiently.

Concurrent vs. Sequential Pursuit

The Opioid Stewardship Designation can be pursued concurrently with your primary URAC accreditation (adding four standards to the existing workload) or sequentially after accreditation is awarded. IHS recommends concurrent pursuit when your primary accreditation already requires clinical protocol development and policy infrastructure — the marginal effort for the designation is substantially lower when foundational documentation is already being built.

Common Challenges Organizations Face

Despite the manageable four-standard scope, organizations encounter predictable obstacles in pursuing the Opioid Stewardship Designation. IHS has identified these patterns across its consulting engagements.

1. Treating the Designation as a Policy Exercise, Not an Operational One

The problem: Organizations draft policies that satisfy the letter of each standard but lack operational implementation — no monitoring data, no training records, no escalation evidence. URAC reviews operational reality, not policy text.

How IHS addresses it: Our engagement begins with operations, not policy. We map what your organization is actually doing with opioid prescribing and dispensing, identify where documentation is missing, and build policies that reflect operational reality — not aspirational statements.

2. Inadequate Leadership Commitment and Resource Allocation

The problem: Opioid stewardship programs require cross-functional ownership — pharmacy, clinical, compliance, and sometimes IT. Organizations that assign the designation to a single compliance staff member without executive sponsorship struggle to generate the operational evidence required.

How IHS addresses it: We advise on governance structure at the outset, identifying the appropriate clinical and operational owners for each of the four standard areas.

3. Data Collection and Monitoring Gaps

The problem: Opioid stewardship requires documented monitoring — tracking opioid prescribing patterns, patient adherence, aberrant behavior, and outcomes. Many organizations lack systematic data collection aligned with URAC's standards.

How IHS addresses it: We provide monitoring framework templates that align with URAC's interpretive information and identify the minimum data elements required for compliant evidence generation.

4. Misalignment with the Primary Accreditation

The problem: Organizations pursuing the Opioid Stewardship Designation alongside a primary accreditation sometimes treat them as independent workstreams, creating redundant or conflicting documentation.

How IHS addresses it: We integrate the designation standards into the primary accreditation engagement from the outset, ensuring that opioid stewardship documentation builds on — rather than duplicates — the primary accreditation evidence framework.

5. Interpretive Information Gaps

The problem: URAC standards carry interpretive information that defines how each standard is evaluated in practice. Organizations without URAC-specific expertise apply generic opioid stewardship frameworks that do not map to URAC's specific evaluation criteria.

How IHS addresses it: Thomas G. Goddard, JD, PhD — former Chief Operating Officer and General Counsel of URAC — brings authoritative knowledge of how URAC constructs and applies its standards. IHS provides URAC-specific interpretation, not generic opioid stewardship guidance.

Why IHS for URAC Opioid Stewardship Designation

IHS brings a combination of URAC-specific expertise and pharmacy program depth that no other consulting firm can match. Thomas G. Goddard, JD, PhD, served as the former Chief Operating Officer and General Counsel of URAC — the organization that wrote these standards. That is not a marketing claim. It means IHS understands how URAC's standards are constructed, how reviewers are trained to apply interpretive information, and where organizations reliably fall short.

What Sets IHS Apart for This Designation

  • Former URAC executive leadership — no other consulting firm can offer direct, firsthand knowledge of URAC's standard development and review methodology
  • Integrated accreditation approach — IHS coordinates Opioid Stewardship Designation pursuit with your primary URAC accreditation, preventing redundant work and conflicting documentation
  • Pharmacy program breadth — IHS consults across URAC Specialty Pharmacy, Mail Service Pharmacy, PBM Accreditation, and Health Plan programs — the most common associated programs for Opioid Stewardship Designation eligibility
  • Operations-first orientation — IHS does not produce policy binders. We build operational compliance and the documentation that proves it
  • RFI support through resolution — if URAC issues a Request for Information, IHS remains engaged through committee decision

Adjacent IHS Services

The Opioid Stewardship Designation is most commonly pursued alongside:

IHS also provides compliance program development for organizations that need to build opioid stewardship infrastructure outside of a URAC accreditation cycle.

Frequently Asked Questions

What is the URAC Opioid Stewardship Designation?

The URAC Opioid Stewardship Designation is an optional add-on designation that supplements an existing URAC accreditation or certification. It comprises four standards focused on patient safety, appropriate opioid use, innovation in opioid management, and reducing substance use disorder risk. It is not a standalone program — applicants must hold or be actively pursuing an associated URAC program (URAC).

Who is eligible?

Organizations must hold or be actively seeking an associated URAC program and must provide for or impact patient access to or use of opioid medications. Associated programs span URAC's pharmacy suite (Specialty Pharmacy, Mail Service, PBM), health plan programs, patient care management, and digital health and telehealth programs.

Is the designation required?

It is voluntary. However, payers, health systems, and state contracting authorities increasingly use voluntary designations as differentiators in contract awards and network inclusion decisions. Organizations in competitive specialty pharmacy and PBM markets report using the designation to signal opioid safety commitment to payers.

How many standards does it include?

Four standards. The focused standard set makes the designation more attainable than a full URAC accreditation, but each standard requires operational evidence, aligned policies, and staff training documentation.

Can it be pursued concurrently with our primary URAC accreditation?

Yes, and IHS recommends concurrent pursuit when your primary accreditation already requires clinical protocol and policy development. The marginal effort for the designation is substantially lower when foundational infrastructure is already being built for the primary accreditation.

What consulting fees does IHS charge?

IHS consulting engagement fees are scoped per engagement based on your organization's specific situation, complexity, and primary accreditation context. Contact us for a tailored proposal.

Related Resources

Ready to Get Started?

Schedule a no-obligation consultation with IHS. We will assess your eligibility, identify the fastest path to the Opioid Stewardship Designation alongside your primary URAC program, and give you a clear roadmap.

Schedule a Free Discovery Session